INS and diabetes mellitus: Before admission, 72% of the treated diabetes group received a dipeptidyl peptidase-4 inhibitor, 40% metformin, 8% pioglitazone, 44% sodium glucose transporter 2 inhibitors, 4% glucagon-like peptide 1 analog, and 12% insulin.